Literature DB >> 33963442

Nanoparticle-based approaches to target the lymphatic system for antitumor treatment.

Xingzhou Peng1, Junjie Wang2, Feifan Zhou1, Qian Liu3, Zhihong Zhang4,5.   

Abstract

Immunotherapies have been established as safe and efficient modalities for numerous tumor treatments. The lymphatic system, which is an important system, can modulate the immune system via a complex network, which includes lymph nodes, vessels, and lymphocytes. With the deepening understanding of tumor immunology, a plethora of immunotherapies, which include vaccines, photothermal therapy, and photodynamic therapy, have been established for antitumor treatments. However, the deleterious off-target effects and nonspecific targeting of therapeutic agents result in low efficacy of immunotherapy. Fortunately, nanoparticle-based approaches for targeting the lymphatic system afford a unique opportunity to manufacture drugs that can simultaneously tackle both aspects, thereby improving tumor treatments. Over the past decades, great strides have been made in the development of DC vaccines and nanomedicine as antitumor treatments in the field of lymphatic therapeutics and diagnosis. In this review, we summarize the current strategies through which nanoparticle technology has been designed to target the lymphatic system and describe applications of lymphatic imaging for the diagnosis and image-guided surgery of tumor metastasis. Moreover, improvements in the tumor specificity of nanovaccines and medicines, which have been realized through targeting or stimulating the lymphatic system, can provide amplified antitumor immune responses and reduce side effects, thereby promoting the paradigm of antitumor treatment into the clinic to benefit patients.

Entities:  

Keywords:  Combinational immunotherapy; DC vaccine; Image-guided therapy; Lymphatic targeting; Lymphoscintigraphy; Nanoplatform; Tumor metastasis

Year:  2021        PMID: 33963442     DOI: 10.1007/s00018-021-03842-6

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  158 in total

Review 1.  Cytokines in cancer pathogenesis and cancer therapy.

Authors:  Glenn Dranoff
Journal:  Nat Rev Cancer       Date:  2004-01       Impact factor: 60.716

2.  Melanoma in 2015: Immune-checkpoint blockade - durable cancer control.

Authors:  Elizabeth I Buchbinder; F Stephen Hodi
Journal:  Nat Rev Clin Oncol       Date:  2016-01-20       Impact factor: 66.675

Review 3.  Adaptive Immune Resistance: How Cancer Protects from Immune Attack.

Authors:  Antoni Ribas
Journal:  Cancer Discov       Date:  2015-08-13       Impact factor: 39.397

Review 4.  HEVs, lymphatics and homeostatic immune cell trafficking in lymph nodes.

Authors:  Jean-Philippe Girard; Christine Moussion; Reinhold Förster
Journal:  Nat Rev Immunol       Date:  2012-09-28       Impact factor: 53.106

Review 5.  Drug delivery to the lymphatic system: importance in future cancer diagnosis and therapies.

Authors:  Yumei Xie; Taryn R Bagby; M S Cohen; M Laird Forrest
Journal:  Expert Opin Drug Deliv       Date:  2009-08       Impact factor: 6.648

Review 6.  Adapting Cancer Immunotherapy Models for the Real World.

Authors:  Lauryn E Klevorn; Ryan M Teague
Journal:  Trends Immunol       Date:  2016-04-19       Impact factor: 16.687

Review 7.  The blockade of immune checkpoints in cancer immunotherapy.

Authors:  Drew M Pardoll
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

8.  [Somatic polysaccharide-containing antigens of the plague bacterium].

Authors:  E E Bakhrakh; V I Veĭnblat
Journal:  Zh Mikrobiol Epidemiol Immunobiol       Date:  1972-03

Review 9.  Cancer nanomedicine: progress, challenges and opportunities.

Authors:  Jinjun Shi; Philip W Kantoff; Richard Wooster; Omid C Farokhzad
Journal:  Nat Rev Cancer       Date:  2016-11-11       Impact factor: 60.716

Review 10.  Tumor-associated macrophages: from mechanisms to therapy.

Authors:  Roy Noy; Jeffrey W Pollard
Journal:  Immunity       Date:  2014-07-17       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.